BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• Press Releases

  Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

  July 6, 2026

   · 

  9 min read
• Press Releases

  Novo Nordisk A/S - share repurchase programme - July 6, 2026

  July 6, 2026

   · 

  2 min read
• Press Releases

  AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

  July 6, 2026

   · 

  9 min read
• Press Releases

  Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

  July 6, 2026

   · 

  9 min read
• Press Releases

  Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

  July 6, 2026

   · 

  4 min read
• Press Releases

  Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London

  July 6, 2026

   · 

  13 min read
• 

  Deals

  Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree

  The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations of existing therapies.

  July 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors

  BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.

  July 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

  July 6, 2026

   · 

  7 min read
• 

  IPO

  Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios

  Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases.

  July 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac